Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Burning Rock Biotech (BNR) EBIAT (2019 - 2025)

Burning Rock Biotech has reported EBIAT over the past 7 years, most recently at -$2.2 million for Q4 2025.

  • For Q4 2025, EBIAT rose 80.26% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached -$7.7 million, up 83.87%, while the annual FY2025 figure was -$7.8 million, 83.57% up from the prior year.
  • EBIAT for Q4 2025 was -$2.2 million at Burning Rock Biotech, up from -$2.3 million in the prior quarter.
  • Over five years, EBIAT peaked at -$1.3 million in Q2 2025 and troughed at -$41.2 million in Q1 2022.
  • A 5-year average of -$20.9 million and a median of -$23.5 million in 2023 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 251.04% in 2021 and later soared 91.01% in 2025.
  • Year by year, EBIAT stood at -$39.4 million in 2021, then increased by 20.45% to -$31.4 million in 2022, then grew by 27.12% to -$22.8 million in 2023, then soared by 51.26% to -$11.1 million in 2024, then surged by 80.26% to -$2.2 million in 2025.
  • Business Quant data shows EBIAT for BNR at -$2.2 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.3 million in Q2 2025.